UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________
Form
_________________________________
(Mark One)
For the quarterly period ended
or
For the transition period from to .
Commission File No.
____________________________________
(Exact name of registrant as specified in its charter)
____________________________________
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered |
| OTC |
Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Indicate by check mark whether
the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
☐ No
shares of common stock, par value $.001 per share, outstanding as of March 14, 2025.
ODYSSEY HEALTH, INC.
FORM 10-Q
For the Quarter Ended January 31, 2025
INDEX
| 2 |
PART I - FINANCIAL INFORMATION
| Item 1. | Financial Statements |
Odyssey Health, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
| January 31, | July 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Research and development rebate due from Australian government | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Investment | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders' Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued wages | ||||||||
| Accrued interest | ||||||||
| Asset purchase liability | ||||||||
| Notes payable, officers and directors | ||||||||
| Notes payable, net of unamortized debt discount and closing costs of $ | ||||||||
| Total current liabilities | ||||||||
| Commitments and contingencies | ||||||||
| Stockholders' deficit: | ||||||||
| Preferred stock, $ par value, shares authorized, shares issued or outstanding | ||||||||
| Common stock, $ par value, shares authorized, and shares issued and outstanding | ||||||||
| Additional paid-in-capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders' deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders' deficit | $ | $ | ||||||
The accompanying notes are an integral part of these
condensed consolidated financial statements.
| 3 |
Odyssey Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended January 31, | Six Months Ended January 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Research and development expense | $ | $ | $ | $ | ||||||||||||
| Stock-based compensation | ||||||||||||||||
| General and administrative expense | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gain on sale of asset | ||||||||||||||||
| Investment revaluation | ( | ) | ( | ) | ( | ) | ||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense), net | ( | ) | ( | ) | ||||||||||||
| Net income (loss) | ( | ) | ( | ) | ||||||||||||
| Deemed dividend | ( | ) | ( | ) | ||||||||||||
| Net income (loss) attributable to common shareholders | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Basic net income (loss) per share | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Diluted net income (loss) per share | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Shares used for basic net income (loss) per share | ||||||||||||||||
| Shares used for diluted net income (loss) per share | ||||||||||||||||
The accompanying notes are an integral part of these
condensed consolidated financial statements.
| 4 |
Odyssey Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders' Deficit
(Unaudited)
| Common Stock | Additional Paid-In | Accumulated | Total | |||||||||||||||||
| Shares | Dollars | Capital | Deficit | Deficit | ||||||||||||||||
| Balances, July 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | – | |||||||||||||||||||
| Warrants issued in debt financing | – | |||||||||||||||||||
| Net loss | – | ( | ) | ( | ) | |||||||||||||||
| Balances, October 31, 2024 | ( | ) | ( | ) | ||||||||||||||||
| Stock-based compensation | – | |||||||||||||||||||
| Net loss | – | ( | ) | ( | ) | |||||||||||||||
| Balances, January 31, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Common Stock | Additional Paid-In | Accumulated | Total | |||||||||||||||||
| Shares | Dollars | Capital | Deficit | Equity | ||||||||||||||||
| Balances, July 31, 2023 | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||
| Stock-based compensation | – | |||||||||||||||||||
| Common stock issued in debt financing | ||||||||||||||||||||
| Common stock issued in equity financings | ||||||||||||||||||||
| Warrants exercised in connection with debt financing | ( | ) | ||||||||||||||||||
| Warrants issued in debt financing | – | |||||||||||||||||||
| Return of shares | ( | ) | ( | ) | ||||||||||||||||
| Net loss | – | ( | ) | ( | ) | |||||||||||||||
| Balances, October 31, 2023 | ( | ) | ( | ) | ||||||||||||||||
| Stock-based compensation | – | |||||||||||||||||||
| RSUs issued | ( | ) | ||||||||||||||||||
| Common stock issued in debt financing | ||||||||||||||||||||
| Common stock issued in equity financings | ||||||||||||||||||||
| Deemed dividend | – | ( | ) | |||||||||||||||||
| Net income | – | |||||||||||||||||||
| Balances, January 31, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 5 |
Odyssey Health, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Six Months Ended January 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | ( | ) | $ | ||||
| Adjustments to reconcile net income (loss) to net cash flows used in operating activities: | ||||||||
| Amortization | ||||||||
| Stock-based compensation | ||||||||
| Financing costs paid via issuance of common stock | ||||||||
| Amortization of debt discount and closing costs | ||||||||
| Allowance for research and development rebut due | ||||||||
| Unrealized losses on investment | ||||||||
| Gain on sale of asset | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| (Increase) decrease in prepaid expenses and other current assets | ( | ) | ||||||
| Decrease in research and development rebate due | ||||||||
| Increase (decrease) in accounts payable | ( | ) | ||||||
| Increase (decrease) in accrued wages | ( | ) | ||||||
| Increase in accrued interest | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Cash proceeds from sale of assets | ||||||||
| Net cash provided by investing activities | ||||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from notes payable | ||||||||
| Principal payments made on notes payable | ( | ) | ||||||
| Interest payments made on notes payable | ( | ) | ||||||
| Proceeds from equity financing | ||||||||
| Net cash provided by financing activities | ||||||||
| Increase in cash | ||||||||
| Cash: | ||||||||
| Beginning of period | ||||||||
| End of period | $ | $ | ||||||
| Supplemental disclosure of cash information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Supplemental disclosure of non-cash information: | ||||||||
| Common stock issued for principal conversion of notes payable | $ | $ | ||||||
| Increase in principal of notes payable | ||||||||
| Shares issued for exercised warrants | ||||||||
| Return of shares | ||||||||
| Deemed dividend | ||||||||
| Warrants issued in connection with debt financing | ||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 6 |
Odyssey Health, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Basis of Presentation, Nature of Operations and Going Concern
Basis of Presentation
The accompanying condensed consolidated financial information of Odyssey Health, Inc. and our wholly-owned subsidiary Odyssey Group International Australia, Pty Ltd, (collectively, the “Company”) is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the consolidated financial position, results of operations and cash flows for the interim periods. The consolidated financial information as of July 31, 2024, is derived from our 2024 Annual Report on Form 10-K. The consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2024 Annual Report on Form 10-K filed with the SEC on November 13, 2024. The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.
Significant Accounting Policies
Our significant accounting policies have not changed during the six months ended January 31, 2025, from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2024.
Nature of Operations
Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have superior clinical utility and serve an unmet medical need. Our business model is to develop or acquire medical related products, engage third parties to help develop, complete clinical trials and manufacture products according to FDA regulations. We have two different technologies in development; the CardioMap® heart monitoring and screening device and the Save a Life choking rescue device.
We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products, and we will apply for trademarks and patents once we have developed proprietary products.
We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration (“FDA”) clearance or approval to market our products will be required to sell in the United States. In addition, we would require additional European Union or country specific clearance or approvals to sell internationally.
Going Concern
We did not recognize any revenues for the year ended
July 31, 2024, or the six months ended January 31, 2025, and we had an accumulated deficit of $
| 7 |
The operating deficit and negative working capital at January 31, 2025 indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations.
The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.
We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.
Note 2. New Accounting Pronouncements
ASU 2023-07
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, which provides amendments to reportable segment disclosure requirements requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new segment disclosures are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. We are currently evaluating this ASU to determine its impact on our disclosures.
ASU 2023-09
In December 2023, the FASB issued ASU 2023-09, Income Taxes, which enhances the transparency of income tax disclosures by expanding annual disclosure requirements related to the rate reconciliation and income taxes paid. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating this ASU to determine its impact on our disclosures.
ASU 2024-03
In November 2024, the FASB issued ASU 2024-03 related to the disaggregation of certain income statement expenses. The amendments in this update require public entities to disclose incremental information related to purchases of inventory, team member compensation and depreciation, which will provide investors the ability to better understand entity expenses and make their own judgements about entity performance. The amendments in this update are effective for fiscal years beginning after December 15, 2026. We plan to adopt this pronouncement and make the necessary updates to our disclosures for the year ending December 31, 2027, and, aside from these disclosure changes, we do not expect the amendments to have a material effect on our financial statements.
| 8 |
Note 3. Investment
Investment consists of shares of Oragenics, Inc. (“Oragenics”) common stock which is valued quarterly based on the common stock price as reported by the NYSE American stock exchange. Our 511,308 shares of Oragenics common stock represented 4.2% of the outstanding shares of Oragenics common stock as reported by Oragenics on November 13, 2024.
We also hold shares of Oragenics convertible Series F preferred stock (the “Preferred Stock”) which is accounted for at cost minus impairments as it is not currently listed on a registered securities exchange. The Preferred Stock is not accounted for as an equity-method investment as it does not have voting rights nor board representation and management does not have significant influence over Oragenics. The Preferred Stock currently has a value of zero.
See also Note 4.
Note 4. Fair Value
The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows:
Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities.
Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability.
Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management.
The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the six months ended January 31, 2025 or the year ended July 31, 2024.
The carrying values of cash, prepaid expenses and other current assets, accounts payable and accrued wages approximate their fair value due to their short maturities.
No changes were made to our valuation techniques during the quarter ended January 31, 2025.
| 9 |
Our financial instruments that are carried at fair value consist of our common stock of Oragenics as follows:
| January 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Oragenics common stock | $ | $ | $ | $ | ||||||||||||
| July 31, 2024 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Oragenics common stock | $ | $ | $ | $ | ||||||||||||
Valuation of Oragenics Common Stock
Our 511,308 shares of Oragenics common stock were valued at $0.31 per share on January 31, 2025, as quoted on the NYSE American Stock Exchange.
Contingent Liabilities
At January 31,
2025 and July 31, 2024, we had contingent consideration related to the acquisition of intellectual property, know-how and patents
for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling
$
We also had contingent consideration at January 31, 2025 and July 31, 2024 related to milestones in our Asset Purchase Agreement with Prevacus, Inc. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). Based on these reviews, the fair value of the contingent consideration was determined to be zero at both periods as it is not yet probable that any of the milestones will be met.
Fixed-Rate Debt
We have fixed-rate debt that is reported on our condensed consolidated balance sheets at carrying value less unamortized debt discount and closing costs. The fair value of our fixed-rate debt was calculated using a discounted cash flow methodology with estimated current interest rates based on similar risk profile and duration (Level 2). The carrying value, excluding unamortized debt discount and debt issuance costs, and the fair value of our fixed-rate long-term debt were as follows:
January 31, 2025 | July 31, 2024 | |||||||
| Carrying value | $ | $ | ||||||
| Fair value | $ | $ | ||||||
Note 5. Debt
LGH Investments, LLC
On September 29, 2022, we entered into Amendment No.
3 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”).
Pursuant to Amendment No. 3, the maturity date of the note was extended to
On November 10, 2022, LGH provided notice to convert
$
| 10 |
On December 29, 2022, we
entered into Amendment No. 4 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant
to the Amendment No. 4, the maturity date of the note was extended to
On March 31, 2023, we entered
into Amendment No. 5 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant to
the Amendment No. 5, the maturity date of the note was extended to
On July 6, 2023, we entered into Amendment No. 6 to
the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant to the Amendment No. 6, the
maturity date of the note was extended to
On August 28, 2023, we paid LGH $
On December 30, 2023, we entered into Amendment No.
7 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant to the Amendment, the
maturity date of the note was extended to
On June 30, 2024, we entered into Amendment No. 8 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant to the Amendment, the maturity date of the note was extended to December 31, 2024. As consideration the note conversion price was changed to $0.072 per common share.
On February 18, 2025, and effective December 31, 2024, we entered into Amendment No. 9 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH. Pursuant to the Amendment, the maturity date of the note was extended to July 31, 2025.
Following these amendments and payments, at January
31, 2025, there was $
Accredited Investor Promissory Note
On August 14, 2024, we entered into a $
Accredited Investor Promissory Note Amendment
On February 13, 2024, we entered into a six-month
promissory note for $
| 11 |
Mast Hill Fund L.P.
On December 13, 2022, we entered into a Securities
Purchase Agreement (the “SPA”) with Mast Hill Fund, L.P. Pursuant to the SPA, we sold Mast Hill (i) an $
On June 13, 2023, we entered into Amendment No. 1
to the SPA dated December 13, 2022. Pursuant to the Amendment, we (i) increased the principal balance by $
On March 13, 2024, we entered into Amendment No. 2
to the Securities Purchase Agreement dated December 13, 2022, with Mast Hill. Pursuant to the Amendment, the $
Mast Hill converted the following amounts of principal, interest and fees to shares of our common stock:
| Date | Principal | Interest | Fees | Total | Conversion price per share | Number of shares of our common stock received | ||||||||||||||||||
| June 15, 2023 | $ | $ | $ | $ | $ | |||||||||||||||||||
| October 9, 2023 | ||||||||||||||||||||||||
| November 6, 2023 | ||||||||||||||||||||||||
| November 9, 2023 | ||||||||||||||||||||||||
| December 22, 2023 | ||||||||||||||||||||||||
| January 18, 2024 | ||||||||||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||||||||||
Payments made to Mast Hill were as follows:
| Date | Principal | Interest | Total | |||||||||
| September 13, 2023 | $ | $ | $ | |||||||||
| October 6, 2023 | ||||||||||||
| December 13, 2023 | ||||||||||||
| Total | $ | $ | $ | |||||||||
On August 7, 2023, Mast Hill converted their outstanding warrant exercisable for shares in a cashless exercise. The conversion resulted in the purchase of shares of our common stock at an exercise price of $0.075 per share. Following this conversion, no shares remained available pursuant to this warrant.
| 12 |
Due to the remaining 5,000,000 Mast Hill warrants
containing a down-round provision, which was triggered prior to July 31, 2023, we issued an additional
On March 14, 2024, Mast Hill converted their outstanding
warrant for shares of our common stock in a cashless exercise, which resulted in the issuance of shares of our common
stock at an exercise price of $0.072 per share. Following this exercise, Mast Hill had warrants exercisable for
On October 29, 2024, we entered into Amendment No.
3 to the Securities Purchase Agreement dated December 13, 2022, with Mast Hill. Pursuant to the Amendment, the $
Following these repayments and conversions, at January
31, 2025, there was $
Directors and Officers Promissory Notes
On December 21, 2021 and December 22, 2021, we entered into a total of five Promissory Notes (the “Promissory Notes”) with three of our directors and two officers.
Mr. Joseph Michael Redmond,
President and Chief Executive Officer, Ms. Christine M. Farrell, Chief Financial Officer, Mr. Jerome H. Casey, Director, Mr. John P. Gandolfo,
Director, and Mr. Ricky W. Richardson, Director, each loaned us $
On October 19, 2023, John Gandolfo, former director,
exercised his option to convert his convertible note of $
On November 1, 2023, we entered into four Promissory Note Amendments (the “Amendments”) to the Promissory Notes entered into December 21, 2021, and December 22, 2021 with two directors and two officers to extend the maturity date of the Promissory Notes to January 31, 2024. All other terms and conditions remained the same.
On July 31, 2024, we entered into four Promissory
Note Amendments (the “Amendments”) to the Promissory Notes entered into December 21, 2021, and December 22, 2021 with two
directors and two officers to extend the maturity date of the Promissory Notes to
At January 31, 2025, we had $
| 13 |
Notes Payable
The following notes payable were outstanding:
| January 31, 2025 | July 31, 2024 | |||||||
| Convertible note issued to LGH due July 31, 2025, with a set interest amount of $84,000 through July 7, 2023, then an interest rate of 8.0% per annum of outstanding principal and convertible at $0.072 per share | $ | $ | ||||||
| Promissory notes issued to officers and directors due July 31, 2025, with an interest rate of 8.0% per annum and convertible at $0.12 per share | ||||||||
| Accredited investor promissory note due July 31, 2025, with an interest rate of 10% per annum and convertible into 30,000 shares of Oragenics common stock held by us | ||||||||
| Mast Hill convertible promissory note due June 13, 2025, with an interest rate of 10% per annum and convertible at $0.072 per share | ||||||||
| Accredited investor promissory note due August 22, 2025, with an interest rate of 18% per annum | ||||||||
| Unamortized debt discount and closing costs | ( | ) | ( | ) | ||||
| $ | $ | |||||||
2021 Omnibus Stock Incentive Plan
At January 31, 2025,
Stock Options
Stock option activity during the six months ended January 31, 2025 was as follows:
Number of Options | Weighted Average Exercise Price | |||||||
| Options outstanding at July 31, 2024 | $ | |||||||
| Options forfeited | ( | ) | ||||||
| Options expired | ( | ) | ||||||
| Options outstanding at January 31, 2025 | $ | |||||||
Warrants
Warrant activity during the six months ended January 31, 2025 was as follows:
Number of Warrants | Weighted Average Exercise Price | |||||||
| Warrants outstanding at July 31, 2024 | $ | |||||||
| Warrants issued | ||||||||
| Warrants expired | ( | ) | ||||||
| Warrants outstanding at January 31, 2025 | $ | |||||||
| 14 |
Unrecognized Compensation Costs
At January 31, 2025, we had unrecognized stock-based compensation of $, which will be recognized over the weighted average remaining vesting period of years.
Basic earnings per share (“EPS”) is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock and if-converted method. Dilutive potential common shares include outstanding stock options and stock awards.
| Three Months Ended January 31, | Six Months Ended January 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income (loss) attributable to common stockholders used for basic earnings (loss) per share | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Add back convertible debt interest | ||||||||||||||||
| Add back convertible debt amortization | ||||||||||||||||
| Plus: deemed dividend | ||||||||||||||||
| Net income (loss) attributable to common stockholders used for diluted earnings (loss) per share calculations | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Weighted average outstanding shares of common stock used for basic earnings (loss) per share | ||||||||||||||||
| Dilutive effect of convertible debt | ||||||||||||||||
| Dilutive effect of warrants | ||||||||||||||||
| Dilutive effect of stock options | ||||||||||||||||
| Common stock and common stock equivalents used for diluted earnings (loss) per share | ||||||||||||||||
| Earnings (Loss) Per Share | ||||||||||||||||
| Basic | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Diluted | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
The following anti-dilutive securities were excluded from the calculations of diluted net loss per share:
| Three Months Ended January 31, | Six Months Ended January 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Options to purchase common stock | ||||||||||||||||
| Shares issuable upon conversion of convertible notes and related accrued interest | ||||||||||||||||
| Warrants to purchase common stock | ||||||||||||||||
| Total potentially dilutive securities | ||||||||||||||||
| 15 |
Note 8. Related Party Transactions
Due to Officers
The following amounts were due to officers for reimbursement of expenses and were included in accounts payable within the accompanying Condensed Consolidated Balance Sheets:
January 31, 2025 | July 31, 2024 | |||||||
| Joseph M. Redmond, CEO | $ | $ | ||||||
| Christine Farrell, CFO | ||||||||
| $ | $ | |||||||
The amount of unpaid salary and bonus due to our officers was included in accrued wages within the accompanying Condensed Consolidated Balance Sheets and was as follows:
January 31, 2025 | July 31, 2024 | |||||||
| Joseph M. Redmond, CEO | $ | $ | ||||||
| Christine Farrell, CFO | ||||||||
| $ | $ | |||||||
Promissory Notes
See Note 6 for a discussion of $
Note 9. Subsequent Events
Management has performed a review of all events and transactions occurring after January 31, 2025 through the date the accompanying unaudited interim condensed consolidated financial statements were available to be issued for items that would require adjustment to or disclosure in the accompanying unaudited interim condensed consolidated financial statements, noting no such events or transactions.
| 16 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements.
Many possible events or factors could affect our future financial results and performance and could cause actual results or performance to differ materially from those expressed, including those risks and uncertainties described in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024 (“2024 Annual Report”) and those described from time to time in our future reports filed with the Securities and Exchange Commission (the “SEC”). We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
Overview
Our business model is to develop or acquire unique medical related products, engage third parties to develop and manufacture such products and then distribute the products through various distribution channels, including third parties. We have two different technologies in research and development stage; the CardioMap® heart monitoring and screening device, and the Save a Life choking rescue device. To date, none of our product candidates have received regulatory clearance or approval for commercial sale.
We plan to license, improve, and develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly and undertake and engage in direct marketing efforts as we move closer to regulatory approvals. We will determine the most effective distribution method for each unique product we include in our portfolio. We will engage third-party research and development firms that specialize in creating products to assist us in developing our own products, and we will apply for trademarks and patents once we have developed proprietary products.
Recent Funding
Accredited Investor Promissory Note
On August 14, 2024, we entered into a $300,000 promissory note (the “Note”) with an accredited investor. The $300,000 was received on August 22, 2024. The Note has a one-year maturity, becoming due on August 22, 2025, and bears interest at the rate of 18% per annum. In addition, we issued the investor a warrant to purchase 300,000 shares of our common stock at $0.10 per share that expires August 14, 2029, with a fair value of $13,343. At January 31, 2025, $300,000 in principal and $26,149 in accrued interest remained outstanding.
| 17 |
Going Concern
See Note 1 of Notes to Condensed Consolidated Financial Statements.
Significant Accounting Policies and Use of Estimates
During the six months ended January 31, 2025, there were no significant changes to our significant accounting policies and estimates as described in Note 2. Summary of Significant Accounting Policies included in Part II, Item 8. of our Annual Report on Form 10-K for the year ended July 31, 2024, which was filed with the SEC on November 13, 2024.
Results of Operations
We do not currently sell or market any products and we did not have any revenue in the three or six-month periods ended January 31, 2025 or 2024. We will commence actively marketing products after the products and drugs in development have been FDA cleared or approved, but there can be no assurance, however, that we will be successful in obtaining FDA clearance or approval for our products.
| Three Months Ended January 31, | $ | % | ||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Research and development expense | $ | – | $ | 42,765 | $ | (42,765 | ) | -100% | ||||||||
| Stock-based compensation | 36,131 | 677,391 | (641,260 | ) | -95% | |||||||||||
| General and administrative expense | 120,462 | 437,274 | (316,812 | ) | -72% | |||||||||||
| Loss from operations | (156,593 | ) | (1,157,430 | ) | 1,000,837 | -86% | ||||||||||
| Gain on sale of asset | – | 15,900,687 | (15,900,687 | ) | 100% | |||||||||||
| Investment revaluation | – | (1,332,980 | ) | 1,332,980 | 100% | |||||||||||
| Interest expense | (63,431 | ) | (141,601 | ) | 78,170 | 55% | ||||||||||
| Other income (loss), net | (102 | ) | 8,890 | (8,992 | ) | -101% | ||||||||||
| Net income (loss) | (220,126 | ) | 13,277,566 | (13,497,692 | ) | 102% | ||||||||||
| Deemed dividend | – | (63,455 | ) | 63,455 | 100% | |||||||||||
| Net income (loss) attributable to common stockholders | $ | (220,126 | ) | $ | 13,214,111 | $ | (13,434,237 | ) | -102% | |||||||
| Basic net income (loss) per share | $ | 0.00 | $ | 0.14 | $ | (0.14 | ) | -100% | ||||||||
| Diluted net income (loss) per share | $ | 0.00 | $ | 0.12 | $ | (0.12 | ) | -100% | ||||||||
| Six Months Ended January 31, | $ | % | ||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Research and development expense | $ | – | $ | 65,766 | $ | (65,766 | ) | -100% | ||||||||
| Stock-based compensation | 96,618 | 1,000,188 | (903,570 | ) | -90% | |||||||||||
| General and administrative expense | 639,402 | 938,716 | (299,314 | ) | -32% | |||||||||||
| Loss from operations | (736,020 | ) | (2,004,670 | ) | (1,268,650 | ) | -64% | |||||||||
| Gain on sale of asset | – | 16,400,687 | (16,400,687 | ) | -100% | |||||||||||
| Investment revaluation | (370,698 | ) | (1,332,980 | ) | 962,282 | 72% | ||||||||||
| Interest expense | (132,217 | ) | (332,462 | ) | 200,245 | 60% | ||||||||||
| Other income, net | (97 | ) | 8,956 | (9,053 | ) | -101% | ||||||||||
| Net income (loss) | (1,239,032 | ) | 12,739,531 | (13,978,563 | ) | -110% | ||||||||||
| Deemed dividend | – | (63,455 | ) | 63,455 | -100% | |||||||||||
| Net income (loss) attributable to common stockholders | $ | (1,239,032 | ) | $ | 12,676,076 | $ | (13,915,108 | ) | -110% | |||||||
| Basic net income (loss) per share | $ | (0.01 | ) | $ | 0.14 | $ | (0.15 | ) | -108% | |||||||
| Diluted net income (loss) per share | $ | (0.01 | ) | $ | 0.12 | $ | (0.13 | ) | -108% | |||||||
| 18 |
Research and Development Expense
Our Research and development expense includes expenses related to our current projects and include clinical research, design and manufacturing, formulation, regulatory and consultants.
We are not currently working on any projects and, therefore, we did not have any Research and development expense in the three or six months ended January 31, 2025.
Stock-Based Compensation
The decreases in Stock-based compensation for the three and six month periods ended January 31, 2025 compared to the same periods of 2024 were due to no options granted in the three and six month periods ended January 31, 2025 and fewer unvested awards outstanding.
General and Administrative Expense
General and administrative includes expenses related to salaries and related benefits for employees in finance, accounting, sales, administrative and research and development activities, as well as stock-based compensation, costs related to maintaining compliance as a public company and legal and professional fees.
The decreases in General and administrative expense were due to the following:
Three months ended January 31, 2025 compared to three months ended | Six months ended January 31, 2025 compared to six months ended | |||||||
| January 31, 2024 | January 31, 2024 | |||||||
| Increase (decrease) in: | ||||||||
| Business development and investor relations | $ | (41,385 | ) | $ | (96,756 | ) | ||
| Consulting fees | (10,000 | ) | (25,000 | ) | ||||
| Insurance expense | (6,249 | ) | (11,451 | ) | ||||
| Legal and professional fees | (91,247 | ) | (120,179 | ) | ||||
| Public Company Expense | (29,628 | ) | 154,536 | |||||
| Wages | (126,503 | ) | (198,549 | ) | ||||
| Other | (11,800 | ) | (1,915 | ) | ||||
| $ | (316,812 | ) | $ | (299,314 | ) | |||
The decreases in wages and business development and investor relations were due to fewer employees and lower activity throughout the company. The decrease in legal and professional fees was due to lower legal fees incurred.
Gain on Sale of Asset
The gain on sale of asset in fiscal 2024 relates to our sale of our drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as our proprietary powder formulation and its nasal delivery device to Oragenics in December 2023.
| 19 |
Interest Expense
Interest expense includes interest on debt outstanding, as well as the amortization of beneficial conversion feature, debt discount and debt issuance costs. Certain information regarding debt outstanding was as follows:
| Three Months Ended January 31, | Six Months Ended January 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Weighted average debt outstanding | $ | 1,902,147 | $ | 1,724,492 | $ | 1,829,421 | $ | 1,836,816 | ||||||||
| Weighted average interest rate | 10.4% | 8.8% | 10.8% | 8.2% | ||||||||||||
The decreases in interest expense in the three and six month periods ended January 31, 2025, compared to the same periods of 2024 were due to lower amortization of beneficial conversion feature, debt discount and debt issuance costs, partially offset by higher average debt outstanding and higher average interest rates.
Liquidity and Capital Resources
See Recent Funding above for a discussion of our recent financings.
The following table sets forth the primary sources and uses of cash:
| Six Months Ended January 31, | ||||||||
| 2025 | 2024 | |||||||
| Net cash used in operating activities | $ | (295,192 | ) | $ | (967,442 | ) | ||
| Net cash provided by investing activities | – | 1,000,000 | ||||||
| Net cash provided by financing activities | 300,000 | 96,717 | ||||||
To date, we have financed our operations primarily through debt financing and limited sales of our common stock. Our ability to continue to access capital could be affected adversely by various factors, including general market and other economic conditions, interest rates, the perception of our potential future earnings and cash distributions, any unwillingness on the part of lenders to make loans to us and any deterioration in the financial position of lenders that might make them unable to meet their obligations to us. If these conditions continue and we cannot raise funds through a public or private debt financing, or an equity offering, our ability to grow our business may be negatively affected. In such case, we have suspended research and development activities until market conditions improve.
Debt
The following notes payable were outstanding:
| January 31, 2025 | July 31, 2024 | |||||||
| Convertible note issued to LGH due July 31, 2025, with a set interest amount of $84,000 through July 7, 2023, then an interest rate of 8.0% per annum of outstanding principal and convertible at $0.072 per share | $ | 1,035,000 | $ | 1,035,000 | ||||
| Promissory notes issued to officers and directors due July 31, 2025, with an interest rate of 8.0% per annum and convertible at $0.12 per share | 100,000 | 100,000 | ||||||
| Accredited investor promissory note due July 31, 2025, with an interest rate of 10% per annum and convertible into 30,000 shares of Oragenics common stock held by us | 50,000 | 50,000 | ||||||
| Mast Hill convertible promissory note due June 13, 2025, with an interest rate of 10% per annum and convertible at $0.072 per share | 499,667 | 499,667 | ||||||
| Accredited investor promissory note due August 22, 2025, with an interest rate of 18% per annum | 300,000 | – | ||||||
| 1,984,667 | 1,684,667 | |||||||
| Unamortized debt discount and closing costs | (19,646 | ) | (38,134 | ) | ||||
| $ | 1, 965,021 | $ | 1,646,533 | |||||
| 20 |
Inflation
Inflation did not have a material impact on our business and results of operations during the periods being reported on.
Off Balance Sheet Arrangements
We do not have any material off balance sheet arrangements.
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk |
We are a smaller reporting company and are not required to provide information under this item.
| Item 4. | Controls and Procedures |
Evaluation of Disclosure Controls and Procedures
Management, with the participation of our Chief Executive Officer and Chief Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of January 31, 2025. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on the evaluation of our disclosure controls and procedures as of January 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, as a result of the material weaknesses in internal control over financial reporting that are described below, our disclosure controls and procedures were not effective.
As previously reported in our Annual Report on Form 10-K for the fiscal year ended July 31, 2024, management identified the following material weaknesses in internal control over financial reporting:
Insufficient Resources: We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.
Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.
We are committed to improving the internal controls and will (1) continue to use third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts, which will mitigate the lack of segregation of duties until there are sufficient personnel, and (3) may consider appointing additional outside directors and audit committee members in the future.
| 21 |
In light of the material weakness described above, prior to the filing of this Form 10-Q for the period ended January 31, 2025, management determined that key quarterly controls were performed timely and also performed additional procedures, including validating the completeness and accuracy of the underlying data used to support the amounts reported in the quarterly financial statements. These control activities and additional procedures have allowed us to conclude that, notwithstanding the material weaknesses, the financial statements in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with United States GAAP.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 22 |
PART II - OTHER INFORMATION
| Item 1A. | Risk Factors |
There have been no material changes during the six months ended January 31, 2025, to the risk factors discussed in our Annual Report on Form 10-K for the year ended July 31, 2024. If any of the identified risks actually occur, our business, financial condition and results of operations could suffer. The trading price of our common stock could decline and you may lose all or part of your investment in our common stock. The risks and uncertainties described in our Annual Report on Form 10-K for the year ended July 31, 2024, are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business operations.
| Item 5. | Other Information |
During the quarter
ended January 31, 2025, no director or officer of the Company
| Item 6. | Exhibits |
The following exhibits are filed herewith and this list constitutes the exhibit index.
| Exhibit Number | Exhibit Description | |
| 10.1 | Form of Amendment No. 10 to Promissory Note (Filed as Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on February 6, 2025 and incorporated herein by reference). | |
| 10.2 | Amendment No. 10 to Convertible Promissory Note with LGH Investments dated April 5, 2021. (Filed as Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on February 12, 2025 and incorporated herein by reference) | |
| 10.3 | Amendment No. 3 to Promissory Note with accredited investor Jonathan Lutz, dated February 13, 2024 (Filed as Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on February 19, 2025 and incorporated herein by reference) | |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 | |
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934 | |
| 32.1 | Certification of Chief Executive Officer pursuant to Section 1350 | |
| 32.2 | Certification of Chief Financial Officer pursuant to Section 1350 | |
| 101.INS | Inline XBRL Instances Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |
| 23 |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, as of March 14, 2025.
| ODYSSEY HEALTH, INC. | ||
| By: | /s/ Joseph Michael Redmond | |
| Joseph Michael Redmond | ||
| Chief Executive Officer, President and Director | ||
| (Principal Executive Officer) | ||
| By: | /s/ Christine M. Farrell | |
| Christine M. Farrell | ||
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | ||
| 24 |